Cohen, H.; Rotem, S.; Elia, U.; Bilinsky, G.; Levy, I.; Chitlaru, T.; Bar-Haim, E.
T Cell Response following Anti-COVID-19 BNT162b2 Vaccination Is Maintained against the SARS-CoV-2 Omicron B.1.1.529 Variant of Concern. Viruses 2022, 14, 347.
https://doi.org/10.3390/v14020347
AMA Style
Cohen H, Rotem S, Elia U, Bilinsky G, Levy I, Chitlaru T, Bar-Haim E.
T Cell Response following Anti-COVID-19 BNT162b2 Vaccination Is Maintained against the SARS-CoV-2 Omicron B.1.1.529 Variant of Concern. Viruses. 2022; 14(2):347.
https://doi.org/10.3390/v14020347
Chicago/Turabian Style
Cohen, Hila, Shahar Rotem, Uri Elia, Gal Bilinsky, Itzchak Levy, Theodor Chitlaru, and Erez Bar-Haim.
2022. "T Cell Response following Anti-COVID-19 BNT162b2 Vaccination Is Maintained against the SARS-CoV-2 Omicron B.1.1.529 Variant of Concern" Viruses 14, no. 2: 347.
https://doi.org/10.3390/v14020347
APA Style
Cohen, H., Rotem, S., Elia, U., Bilinsky, G., Levy, I., Chitlaru, T., & Bar-Haim, E.
(2022). T Cell Response following Anti-COVID-19 BNT162b2 Vaccination Is Maintained against the SARS-CoV-2 Omicron B.1.1.529 Variant of Concern. Viruses, 14(2), 347.
https://doi.org/10.3390/v14020347